Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

cannabis

  • Home
  •  
  • cannabis



  • Most Read
  • Latest Comments
  • Melodiol seeks redemption under new name and leadership, starts with a strong June quarter
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Melodiol seeks redemption under new name and leadership, starts with a strong June quarter
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Melodiol seeks redemption under new name and leadership, starts with a strong June quarter
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Melodiol seeks redemption under new name and leadership, starts with a strong June quarter
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Melodiol seeks redemption under new name and leadership, starts with a strong June quarter
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • ECS Botanics secures distribution rights to bring Terphogz’s ‘The Original Z’ cannabis strain to Australia
    ECS Botanics secures distribution rights to bring Terphogz’s ‘The Original Z’ cannabis strain to Australia
    • News

  • Bioxyne leads the way as Australia’s first manufacturer of pharmaceutical cannabis gummies
    Bioxyne leads the way as Australia’s first manufacturer of pharmaceutical cannabis gummies
    • News

  • Melodiol moves to clear debt with $12m asset fire sale
    Melodiol moves to clear debt with $12m asset fire sale
    • News

  • Althea to make a splash in the US with new cannabis-based sodas
    Althea to make a splash in the US with new cannabis-based sodas
    • News

  • Melodiol Global Health reports revenue growth amid wider acceptance of medicinal cannabis products
    Melodiol Global Health reports revenue growth amid wider acceptance of medicinal cannabis products
    • News

  • Melodiol seeks redemption under new name and leadership, starts with a strong June quarter
    • News

    Melodiol seeks redemption under new name and leadership, starts with a strong June quarter

    Three CEOs within 18 months, a serious listing breach, and an ASX censure. It seems like the stars were not so aligned for cannabis manufacturing company Creso Pharma’s past (formerly ASX: CPH), but with a fresh leadership and a recent name change to Melodiol (ASX: ME1), the Company is back to chasing its American and

    Read More
    Public
  • Cann Group poised for growth as demand for locally produced cannabis surges
    • News

    Cann Group poised for growth as demand for locally produced cannabis surges

    Australia has made a groundbreaking decision by becoming the first country to legalise the clinical prescribing of MDMA (ecstasy) and psilocybin (magic mushrooms) for the treatment of specific mental health disorders, including PTSD and treatment-resistant depression. Setting Australia apart as the pioneer in adopting psychoactive-based treatments for mental health, as of 1 July, authorised psychiatrists

    Read More
    Public
  • Treating mental health; TGA approves MDMA and Psilocybin as a medicine
    • News

    Treating mental health; TGA approves MDMA and Psilocybin as a medicine

    Although it doesn’t apply to me, many of you may remember the early mornings during adolescence when you were throwing yourself around in a club, parading a locked-jaw, and beaming pupils so wide it would be hard to deny that you weren’t on something. Well, chances are, you had consumed MDMA, or if you were

    Read More
    Public
  • Little Green Pharma gets green light ‘ethics approval’ from TGA ahead of SleepWell study
    • News

    Little Green Pharma gets green light ‘ethics approval’ from TGA ahead of SleepWell study

    Cannabis company, Little Green Pharma (ASX: LGP) has been growing its market share all while pleasing investors with its latest announcement that it has obtained an Ethics Approval for its proposed Australian-based, multi-site, placebo-controlled ‘SleepWell Study’ where it will be trialling the Company’s LGP Classic CBD 50 cannabis oil medicine and its effectiveness on stress

    Read More
    Public
  • Incannex plugs Eurofin Scientific to kick off research into newly discovered cannabinoid
    • News

    Incannex plugs Eurofin Scientific to kick off research into newly discovered cannabinoid

    The pharma company developing therapies for unmet needs with the use of medicinal cannabinoids and psychedelics, Incannex Healthcare (ASX: IHL), has been on the move recently and has engaged Eurofins Scientific to manufacture the Company’s ReneCann therapeutic topical application drug. Eurofins Scientific, which is a French group of laboratories based out of Luxemburg, is a

    Read More
    Public
  • Little Green Pharma winds down German distribution deal
    • News

    Little Green Pharma winds down German distribution deal

    A key player in the global cannabis market, Little Green Pharma (ASX: LGP), has pulled the plug on its German distributor, Four 20 Pharma GmbH, after failing to meet the contract terms to bring a highly-prospective new THC strain to the German medical cannabis market by 19th November 2022. Licensed as a manufacturer, wholesaler, and

    Read More
    Public
  • «
  • ‹
  • 2
  • 3
  • 4
  • 5
  • 6
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.